Global Acne Medication Market is slated to showcase remarkable growth and record a sizeable valuation by 2032, owing to rising consumer awareness regarding several acne treatment options. There has been a considerable surge in the number of consumers undergoing treatment for various acne conditions, attributed to the increased cognizance of the benefits of acne medication in efficiently treating acne issues.
Acne treatment involves the use of multiple antibiotics for prolonged periods. Therefore the awareness about their potential side effects, antibiotic resistance, and alternative options stand critical among patients. Based on a survey conducted in 2019, approximately 86% of the respondents were aware of the ingredients and potential side effects of acne medications. In addition, the rising inclination toward improving facial aesthetics will accelerate business growth throughout the projection period.
The acne medication market is segregated based on formulation, product, type, acne, distribution channel, and region.
With respect to the formulation, the topical segment is expected to drive lucrative growth between 2023 and 2032. The segment growth can be credited to the proven benefits of topical acne medications in controlling bacterial growth, reducing inflammation and clogged pores, and their effectiveness in treating mild to severe acne.
Speaking of the product category, the benzoyl peroxide segment amassed over USD 1.2 billion in 2022. Benzoyl peroxide is an FDA-approved prescription acne medication that is also available over the counter to treat severe acne. When combined with other therapies, benzoyl peroxide can effectively treat acne vulgaris owing to its mild keratolytic & sebostatic effects, thus bolstering its adoption throughout the forecast timeframe.
Based on type, the over-the-counter segment is poised to record an appreciable valuation by 2032. Over-the-counter acne medication products contain active ingredients such as benzoyl peroxide and salicylic acid that significantly control oil secretion, inflammation, and redness. This allows existing blemishes and acne to shrink while preventing new ones from forming, thus increasing product acceptance.
Regarding acne, the non-inflammatory segment is anticipated to grow at a decent CAGR through the study timeframe. Non-inflammatory acne is recognized as comedones (blackheads and whiteheads). These usually do not involve any redness or inflammation and are easier to treat than inflammatory acne. The effectivity of several medications, such as salicylic acids, in reducing their appearance will significantly transform the market dynamics.
The retail stores segment size is projected to exceed USD 8.5 billion by 2032. Retail stores have a decent expansion rate, increased accessibility, and deep penetration of acne care products. Estimations suggest that there were almost 1,045,000 retail stores in the U.S. in 2020. The increasing dominance of brick-and-mortar retail store models across major world economies will create favorable growth prospects for the acne medication market.
Regionally, the Asia Pacific region clocked more than USD 1.9 billion in 2022 and is set to exhibit over 6.5% CAGR through 2032. The increased availability of suitable treatment options across the region and the rapid transformation in consumer buying behavior may propel product sales. Besides, the improving economic landscape coupled with the untapped potential and a high target addressable market will boost the growth of the Asia Pacific acne medication industry.